SkylineDx's Merlin Melanoma Assay shows its ability to reduce SLNB by over 40% in a Danish Multicenter Validation Study

SkylineDx Netherlands United Kingdom United States of America

In the independent blinded validation study, Merlin accurately identifies melanoma patients at low risk of metastatic disease, including sentinel lymph node metastasis The potential SLNB surgery reduction rate is above 70% in pT1 patientsand www.merlinmelanomatest.com.

About SkylineDx

SkylineDx is a biotechnology company focused on research and development of molecular diagnostics in oncology inflammatory, and infectious diseases. SkylineDx uses its expertise to bridge the gap between academically discovered gene expression signatures and commercially available diagnostic products with high clinical utility, assisting healthcare professionals in accurately determining the type or status of disease or predicting a patient's response to treatment. Based on test results, healthcare professionals can tailor the treatment approach to the individual patient. SkylineDx is headquartered in Rotterdam, the Netherlands, complemented by a US base of operations and a CAP/CLIA certified laboratory in San Diego California, USA. To learn more about SkylineDx, please visit www.skylinedx.com. 

Footnotes:

Marie B.-M. Weitemeyer, Neel M. Helvind, Siri Klausen et al.,) Validation of a clinicopathologic and gene expression model for predicting sentinel node metastasis in melanoma: A multicenter Danish cohort study. JSO 2025, Link to the publication.

Media Contact:
ICR Healthcare
Alexis Feinber
[phone]
[e-mail]

View original content:https://www.prnewswire.co.uk/news-releases/skylinedxs-merlin-melanoma-assay-shows-its-ability-to-reduce-slnb-by-over-40-in-a-danish-multicenter-validation-study-302509636.html

@ prnewswire.co.uk